Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02960022




Registration number
NCT02960022
Ethics application status
Date submitted
7/11/2016
Date registered
9/11/2016
Date last updated
12/06/2024

Titles & IDs
Public title
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Scientific title
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Secondary ID [1] 0 0
2016-001694-32
Secondary ID [2] 0 0
9785-CL-0123
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Prostate

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - enzalutamide
Treatment: Drugs - abiraterone acetate
Treatment: Drugs - prednisone

Experimental: enzalutamide - Subjects will receive enzalutamide orally once daily at the same time each day

Experimental: enzalutamide plus abiraterone acetate and prednisone - Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily


Treatment: Drugs: enzalutamide
Subjects will receive enzalutamide orally once daily at the same time each day.

Treatment: Drugs: abiraterone acetate
Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide

Treatment: Drugs: prednisone
Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with adverse events
Timepoint [1] 0 0
Until End of Study (Up to 96 Months)

Eligibility
Key inclusion criteria
* Subject must currently be receiving enzalutamide for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible.
* Subject is able to continue on the treatment regimen that the subject was receiving in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dose change in Androgen deprivation therapy (ADT) or dropping of a combination therapy) approval from a medical monitor is required prior to enrollment.
* Subject is able to swallow enzalutamide capsules and comply with study requirements.
* Subject and female partner who is of childbearing potential must continue to use 2 forms of birth control, of which 1 must be highly effective and 1 must be a barrier method throughout the study and for 3 months after final enzalutamide administration.
* Subject agrees to avoid sperm donation during the study and for at least 3 months after final enzalutamide administration.
* Subject agrees not to participate in another interventional study while on treatment.

Canada Specific:

* Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization for the United States sites) must be obtained from the subject prior to any study-related procedures.
* Subject must currently be receiving enzalutamide for breast cancer in a study sponsored by Astellas or Medivation/Pfizer and based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible.
* Subject is able to continue on the treatment regimen that they were receiving in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dropping of a combination therapy) approval from a medical monitor is required prior to enrollment.
* Subject is able to swallow enzalutamide capsules and comply with study requirements.
* Subject is either:
* Of nonchildbearing potential:
* postmenopausal (defined as no spontaneous menses for at least 12 months prior to Day 1 with follicle stimulating hormone (FSH) > 40 IU/L at Day 1 for women < 55 years of age),
* documented surgically sterile or status post hysterectomy (at least 1 month prior to Day 1),
* Or, if of childbearing potential,
* must have a negative urine pregnancy test at Day 1 before the first dose of study drug is administered,
* must use 2 acceptable methods of birth control starting at Day 1 and through 6 months after the final study drug administration,
* must not donate ova starting at first administration of study intervention and throughout 6 months after final study intervention administration.

The 2 acceptable methods of birth control are as follows or per local guidelines where these require additional description of contraceptive methods:

* A barrier method (e.g., condom by a male partner) is required; AND
* One of the following is required:
* Placement of an intrauterine device (IUD) or intrauterine system (IUS);
* Additional barrier method including occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
* Vasectomy or other surgical castration at least 6 months before Day 1.
* The subject must not be breastfeeding at Day 1 or during the study period, and for 6 months after the final study drug administration.
* Subject agrees not to participate in another interventional study while on treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
* Subject met any of the discontinuation criteria or whose cancer progressed on the current enzalutamide clinical study in which subject is enrolling from.
* Subject requires treatment with or plans to use either of the following:

* New systemic therapy for subjects cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment.
* Investigational therapy other than enzalutamide.
* Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide.
* Subject has any concurrent disease, infection, or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.

Canada Specific:

Subject will be excluded from participation if any of the following apply:

* Subject met any of the discontinuation criteria or whose cancer progressed on the current enzalutamide clinical study in which they are enrolling from.
* Subject requires treatment with or plans to use any of the following:
* New systemic therapy for their cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment.
* Investigational therapy other than enzalutamide.
* Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide.
* Subject has any concurrent disease, infection, or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data in the opinion of the investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/12/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/07/2026
Actual
Sample size
Target
900
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Site AU61014 - Albury
Recruitment hospital [2] 0 0
Site AU61001 - Tweed Heads
Recruitment hospital [3] 0 0
Site AU61017 - Wahroonga
Recruitment hospital [4] 0 0
Site AU61006 - Ashford
Recruitment hospital [5] 0 0
Site AU61019 - Ballarat
Recruitment hospital [6] 0 0
Site AU61007 - East Bentleigh
Recruitment hospital [7] 0 0
Site AU61009 - Malvern
Recruitment hospital [8] 0 0
Site AU61021 - Parkville
Recruitment hospital [9] 0 0
Site AU61008 - South Brisbane
Recruitment hospital [10] 0 0
Site AU61016 - St Albans
Recruitment hospital [11] 0 0
Site AU61004 - Westmead
Recruitment postcode(s) [1] 0 0
2640 - Albury
Recruitment postcode(s) [2] 0 0
2485 - Tweed Heads
Recruitment postcode(s) [3] 0 0
2076 - Wahroonga
Recruitment postcode(s) [4] 0 0
- Ashford
Recruitment postcode(s) [5] 0 0
3350 - Ballarat
Recruitment postcode(s) [6] 0 0
3165 - East Bentleigh
Recruitment postcode(s) [7] 0 0
- Malvern
Recruitment postcode(s) [8] 0 0
- Parkville
Recruitment postcode(s) [9] 0 0
- South Brisbane
Recruitment postcode(s) [10] 0 0
3021 - St Albans
Recruitment postcode(s) [11] 0 0
2145 - Westmead
Recruitment postcode(s) [12] 0 0
- Westmead
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alaska
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Caba
Country [26] 0 0
Argentina
State/province [26] 0 0
Santa Fé
Country [27] 0 0
Argentina
State/province [27] 0 0
Buenos Aires
Country [28] 0 0
Argentina
State/province [28] 0 0
Cordorba
Country [29] 0 0
Argentina
State/province [29] 0 0
San Miguel de Tucuman
Country [30] 0 0
Argentina
State/province [30] 0 0
Tucuman
Country [31] 0 0
Austria
State/province [31] 0 0
Vienna
Country [32] 0 0
Belgium
State/province [32] 0 0
West-Vlaanderen
Country [33] 0 0
Belgium
State/province [33] 0 0
Anderlecht
Country [34] 0 0
Belgium
State/province [34] 0 0
Brussels
Country [35] 0 0
Belgium
State/province [35] 0 0
Gent
Country [36] 0 0
Belgium
State/province [36] 0 0
Hasselt
Country [37] 0 0
Belgium
State/province [37] 0 0
Leuven
Country [38] 0 0
Belgium
State/province [38] 0 0
Liege
Country [39] 0 0
Belgium
State/province [39] 0 0
Turnhout
Country [40] 0 0
Brazil
State/province [40] 0 0
RIO Grande DO SUL
Country [41] 0 0
Brazil
State/province [41] 0 0
Bahia
Country [42] 0 0
Brazil
State/province [42] 0 0
Campinas
Country [43] 0 0
Brazil
State/province [43] 0 0
Ijuí
Country [44] 0 0
Brazil
State/province [44] 0 0
Jau
Country [45] 0 0
Brazil
State/province [45] 0 0
Rio Grande Do Sul
Country [46] 0 0
Brazil
State/province [46] 0 0
Santo Andre
Country [47] 0 0
Canada
State/province [47] 0 0
Ontario
Country [48] 0 0
Canada
State/province [48] 0 0
Quebec
Country [49] 0 0
Canada
State/province [49] 0 0
Abbotsford
Country [50] 0 0
Canada
State/province [50] 0 0
Greenville
Country [51] 0 0
Canada
State/province [51] 0 0
Montreal
Country [52] 0 0
Canada
State/province [52] 0 0
Oakville
Country [53] 0 0
Chile
State/province [53] 0 0
RM
Country [54] 0 0
Chile
State/province [54] 0 0
Valparaiso
Country [55] 0 0
Chile
State/province [55] 0 0
IX Region
Country [56] 0 0
Chile
State/province [56] 0 0
Santiago
Country [57] 0 0
Chile
State/province [57] 0 0
Vina del Mar
Country [58] 0 0
Czechia
State/province [58] 0 0
Olomouc
Country [59] 0 0
Czechia
State/province [59] 0 0
Praha 2
Country [60] 0 0
Czechia
State/province [60] 0 0
Praha 6
Country [61] 0 0
Denmark
State/province [61] 0 0
Nordjylland
Country [62] 0 0
Denmark
State/province [62] 0 0
Aarhus
Country [63] 0 0
Denmark
State/province [63] 0 0
Copenhagen
Country [64] 0 0
Denmark
State/province [64] 0 0
Herlev
Country [65] 0 0
Denmark
State/province [65] 0 0
Vejle
Country [66] 0 0
Finland
State/province [66] 0 0
Tampere
Country [67] 0 0
Finland
State/province [67] 0 0
Turku
Country [68] 0 0
France
State/province [68] 0 0
La Roche sur Yon
Country [69] 0 0
France
State/province [69] 0 0
Lille
Country [70] 0 0
France
State/province [70] 0 0
Lyon Cedex 3
Country [71] 0 0
France
State/province [71] 0 0
Montpellier Cedex
Country [72] 0 0
France
State/province [72] 0 0
Nimes
Country [73] 0 0
France
State/province [73] 0 0
Paris
Country [74] 0 0
France
State/province [74] 0 0
Saint Herblain
Country [75] 0 0
France
State/province [75] 0 0
Strasbourg
Country [76] 0 0
France
State/province [76] 0 0
Villejuif
Country [77] 0 0
Georgia
State/province [77] 0 0
Tbilisi
Country [78] 0 0
Germany
State/province [78] 0 0
Baden-Württemberg
Country [79] 0 0
Germany
State/province [79] 0 0
DE
Country [80] 0 0
Germany
State/province [80] 0 0
NRW
Country [81] 0 0
Germany
State/province [81] 0 0
Bonn
Country [82] 0 0
Germany
State/province [82] 0 0
Hamburg
Country [83] 0 0
Hong Kong
State/province [83] 0 0
Hong Kong
Country [84] 0 0
Israel
State/province [84] 0 0
Jerusalem
Country [85] 0 0
Israel
State/province [85] 0 0
Peth Tikva
Country [86] 0 0
Israel
State/province [86] 0 0
Ramat-Gan
Country [87] 0 0
Israel
State/province [87] 0 0
Tzrifin Beer Yakov
Country [88] 0 0
Italy
State/province [88] 0 0
Emilia Romagna
Country [89] 0 0
Italy
State/province [89] 0 0
Arezzo
Country [90] 0 0
Italy
State/province [90] 0 0
Candiolo
Country [91] 0 0
Italy
State/province [91] 0 0
Cremona
Country [92] 0 0
Italy
State/province [92] 0 0
Forli
Country [93] 0 0
Italy
State/province [93] 0 0
Roma
Country [94] 0 0
Italy
State/province [94] 0 0
Toscana
Country [95] 0 0
Italy
State/province [95] 0 0
Trento
Country [96] 0 0
Japan
State/province [96] 0 0
Chiba
Country [97] 0 0
Japan
State/province [97] 0 0
Fukuoka
Country [98] 0 0
Japan
State/province [98] 0 0
Gunma
Country [99] 0 0
Japan
State/province [99] 0 0
Kagawa
Country [100] 0 0
Japan
State/province [100] 0 0
Kanagawa
Country [101] 0 0
Japan
State/province [101] 0 0
Osaka
Country [102] 0 0
Japan
State/province [102] 0 0
Tokyo
Country [103] 0 0
Japan
State/province [103] 0 0
Yamaguchi
Country [104] 0 0
Japan
State/province [104] 0 0
Kyoto
Country [105] 0 0
Japan
State/province [105] 0 0
Niigata
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Busan
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Seongnam-si
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Seoul
Country [109] 0 0
Malaysia
State/province [109] 0 0
Kuching
Country [110] 0 0
Moldova, Republic of
State/province [110] 0 0
Chisinau
Country [111] 0 0
Netherlands
State/province [111] 0 0
Den Helder
Country [112] 0 0
Netherlands
State/province [112] 0 0
Maastricht
Country [113] 0 0
Netherlands
State/province [113] 0 0
Rotterdam
Country [114] 0 0
New Zealand
State/province [114] 0 0
Auckland
Country [115] 0 0
New Zealand
State/province [115] 0 0
Dunedin
Country [116] 0 0
New Zealand
State/province [116] 0 0
Hamilton
Country [117] 0 0
Norway
State/province [117] 0 0
Stavanger
Country [118] 0 0
Poland
State/province [118] 0 0
Gdansk
Country [119] 0 0
Poland
State/province [119] 0 0
Myslowice
Country [120] 0 0
Poland
State/province [120] 0 0
Pozman
Country [121] 0 0
Poland
State/province [121] 0 0
Slupsk
Country [122] 0 0
Poland
State/province [122] 0 0
Wroclaw
Country [123] 0 0
Romania
State/province [123] 0 0
Bucuresti
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Moscow
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Omsk
Country [126] 0 0
Russian Federation
State/province [126] 0 0
St. Petersburg
Country [127] 0 0
Serbia
State/province [127] 0 0
Belgrade
Country [128] 0 0
Slovakia
State/province [128] 0 0
Bratislava
Country [129] 0 0
Slovakia
State/province [129] 0 0
Kosice
Country [130] 0 0
Slovakia
State/province [130] 0 0
Nitra
Country [131] 0 0
Slovakia
State/province [131] 0 0
Presov
Country [132] 0 0
Slovakia
State/province [132] 0 0
Trencin
Country [133] 0 0
Slovakia
State/province [133] 0 0
Zilina
Country [134] 0 0
South Africa
State/province [134] 0 0
George
Country [135] 0 0
Spain
State/province [135] 0 0
Barcelona
Country [136] 0 0
Spain
State/province [136] 0 0
Gerona
Country [137] 0 0
Spain
State/province [137] 0 0
Madrid
Country [138] 0 0
Spain
State/province [138] 0 0
Pamplona
Country [139] 0 0
Spain
State/province [139] 0 0
Salamanca
Country [140] 0 0
Spain
State/province [140] 0 0
Santiago de Compostela
Country [141] 0 0
Sweden
State/province [141] 0 0
Göteborg
Country [142] 0 0
Sweden
State/province [142] 0 0
Umeå
Country [143] 0 0
Taiwan
State/province [143] 0 0
Gueishan
Country [144] 0 0
Taiwan
State/province [144] 0 0
Kaohsiung
Country [145] 0 0
Taiwan
State/province [145] 0 0
Taichung
Country [146] 0 0
Taiwan
State/province [146] 0 0
Taipei
Country [147] 0 0
Thailand
State/province [147] 0 0
Songkla
Country [148] 0 0
Thailand
State/province [148] 0 0
Bangkok
Country [149] 0 0
Turkey
State/province [149] 0 0
Ankara
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Bebington
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Belfast
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Bristol
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Cambridge
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Cardiff
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Glasgow
Country [156] 0 0
United Kingdom
State/province [156] 0 0
London
Country [157] 0 0
United Kingdom
State/province [157] 0 0
Manchester
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Northwood
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Nottingham
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Astellas Pharma Global Development, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Pfizer
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.
Trial website
https://clinicaltrials.gov/study/NCT02960022
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Associate Medical Director
Address 0 0
Astellas Pharma Global Development, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Astellas Pharma Global Development
Address 0 0
Country 0 0
Phone 0 0
800-888-7704
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02960022